SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 436 participants.
Also called NCT07445789
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 436 participants
- Sponsor
- Martini Hospital Groningen
- Registry
-
NCT07445789 -
2025-524245-27-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07445789. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2029-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation
- Acronym
- SMART-VERAPAF
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- Verapamil 240 mg slow-release tablet
- Intervention (Drug)
- metoprolol 100 mg slow-release tablet
- Lead sponsor
- Martini Hospital Groningen
Record details
- Record id
cardio:ct-nct07445789- Content hash
7672975258b7a651327d785bdc2213777f79d67ddf2ad227a2ad95e1dff4baf5